Success for Pentracor at the German Medical Award 2020

Hennigsdorf, 20.11.2020 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved indirect success with its medical product PentraSorb® CRP. At the German Medical Award 2020, Prof. Dr. Jan Torzewski, head physician of the Heart and Vascular Center of the Allgäu Hospital Association at Kempten Hospital and a specialist in cardiology and intensive care medicine, secured 2nd place among 34 renowned participants.

2nd place for Prof. Torzewski at the GMA

He was awarded in the category 'Medical Innovation Practices & Clinics - Cardiology' for the application of the innovative CRP apheresis after myocardial infarction. He prevailed against almost all colleagues, in particular also from university hospitals and heart centers.

The 100th patient was successfully treated with CRP apheresis

Der 100. Patient wurde dieser Tage mit der CRP-Apherese behandelt. Diese Behandlung lief im Rahmen der CABY1-Studie (CRP-Apherese nach koronarer Bypass-Operation) und wurde wie gewohnt sicher durchgeführt. Wir freuen uns, dass nun schon 100 Patienten von der Therapie profitieren konnten und hoffen, noch zahlreichen weiteren Menschen helfen zu können.

Review on CRP apheresis published

In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).

Pentracor GmbH: Bond 2020/2025 successfully placed

Hennigsdorf, June 8, 2020 - The medical technology company Pentracor GmbH, operating in the dynamically growing healthcare sector, has almost completed the placement of its corporate bond with a possible conversion right (ISIN: DE000A289XB9, WKN: A289XB) via private placement with an issue volume of EUR 15 million. Final discussions with potential investors are still ongoing.